Lilly Pharmaceuticals Products

Eli Lilly shares drop

Lilly sues two medical spas over copycat weight-loss drugs

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.

MarketWatch on MSN · 1d

Eli Lilly’s stock falls as weight-loss drug sales disappoint

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.

CNBC on MSN · 1d

Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.

Reuters on MSN · 1d

Lilly forecasts weak sales of weight-loss drug in fourth quarter

Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.

Quartz on MSN · 1d

Eli Lilly was hoping weight loss drug demand would be even bigger

Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.

Hosted on MSN18h

Eli Lilly Cuts Q4 Sales Forecast: ETFs to Buy on the Dip

Eli Lilly and Company LLY dropped 6.6% in the Jan. 14 trading session after slashing its revenue guidance for the fourth quarter and fiscal 2024, citing lower-than-expected sales for its weight-loss ...

FiercePharma1d

JPM25: Eli Lilly's preliminary '24 sales figures show a continued easing in breakneck GLP-1 market

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Eli Lilly & Co.: Positive Long-Term Outlook Despite Recent Setbacks – Buy Rating Affirmed

Analyst Mohit Bansal from Wells Fargo maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at ...

GlobalData on MSN23h

JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

The Pharma Letter21h

Lilly drops on disappointing guidance

Eli Lilly saw its shares close down 6.6% at $744.91 yesterday, after it revealed forecast for sales at the JP Morgan ...

MM&M2d

Obesity meds to lead charge as pharma sales ride ‘momentum’ into 2025

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

Eli Lilly & Co: Strong Growth Prospects and Strategic Investments Justify Buy Rating

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...

FiercePharma12d

Roche projected to claim pharma's 2025 sales crown as Novo, Lilly climb rankings: Evaluate

The story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine ...

6don MSN

Novo, Eli Lilly to dominate global pharma sales in 2025: report

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Yahoo Finance1mon

Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt

Under this agreement, Lilly has been supplying its active pharmaceutical ingredient (API) for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to ...

Eli Lilly to buy cancer drug developer Scorpion Therapeutics for $2.5 bln

Eli Lilly said on Monday it would acquire cancer therapy developer Scorpion Therapeutics for $2.5 billion in cash.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results